Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention

被引：34

作者：

Herrmann, HC

Swierkosz, TA

Kapoor, S

Tardiff, DC

DiBattiste, PM

Hirshfeld, JW

Klugherz, BD

Kolansky, DM

Magness, K

Valettas, N

Wilensky, RL

机构：

[1] Hosp Univ Penn, Philadelphia, PA 19104 USA

[2] Merck & Co Inc, West Point, PA USA

[3] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 89卷 / 11期

关键词：

D O I：

10.1016/S0002-9149(02)02329-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In patients with unstable angina and non-Q-wave, myocardial infarction, the do Tirofiban And ReoPro Give similar Efficacy Trial (TARGET) dose of tirofiban inhibits platelet aggregation less effectively than abciximab near the time of initial balloon inflation. This is likely due to a suboptimal bolus dose of tirofiban and may contribute to the greater event rate observed with tirofiban in TARGET.

引用

收藏

页码：1293 / +

页数：6

相关论文

共 17 条

[1] Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial [J].

Ault, KA ;

Cannon, CP ;

Mitchell, J ;

McCahan, J ;

Tracy, RP ;

Novotny, WF ;

Reimann, JD ;

Braunwald, E .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) :634-639

[2] Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].

Cannon, CP ;

Weintraub, WS ;

Demopoulos, LA ;

Vicari, R ;

Frey, MJ ;

Lakkis, N ;

Neumann, FJ ;

Robertson, DH ;

DeLucca, PT ;

DiBattiste, PM ;

Gibson, CM ;

Braunwald, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887

[3]

Kereiakes DJ, 1996, J AM COLL CARDIOL, V27, P536

[4] Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention [J].

Kereiakes, DJ ;

Broderick, TM ;

Roth, EM ;

Whang, D ;

Shimshak, T ;

Runyon, JP ;

Hattemer, C ;

Schneider, J ;

Lacock, P ;

Mueller, M ;

Abbottsmith, CW .

AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (04) :391-395

[5] Administration of abciximab to patients receiving tirofiban or eptifibatide: Effect on platelet function [J].

Lev, EI ;

Osende, JI ;

Richard, MF ;

Robbins, JA ;

Delfin, JA ;

Rodriguez, O ;

Sharma, SK ;

Jayasundera, T ;

Badimon, JJ ;

Marmur, JD .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (03) :847-855

[6] The Xylum Clot Signature Analyzer®:: A dynamic flow system that simulates vascular injury [J].

Li, CKN ;

Hoffmann, TJ ;

Hsieh, PY ;

Malik, S ;

Watson, WC .

THROMBOSIS RESEARCH, 1998, 92 (06) :S67-S77

[7] Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization [J].

Lincoff, AM ;

Kereiakes, DJ ;

Mascelli, MA ;

Deckelbaum, LI ;

Barnathan, ES ;

Patel, KK ;

Frederick, B ;

Nakada, MT ;

Topol, EJ .

CIRCULATION, 2001, 104 (02) :163-167

[8] Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting [J].

Neumann, FJ ;

Hochholzer, W ;

Pogatsa-Murray, G ;

Schömig, A ;

Gawaz, M .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) :1323-1328

[9]

Osende JI, 2001, CIRCULATION, V103, P1488

[10] Effect of Ca2+ on GP IIb-IIIa interactions with integrilin - Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate [J].

Phillips, DR ;

Teng, W ;

Arfsten, A ;

NannizziAlaimo, L ;

White, MM ;

Longhurst, C ;

Shattil, SJ ;

Randolph, A ;

Jakubowski, JA ;

Jennings, LK ;

Scarborough, RM .

CIRCULATION, 1997, 96 (05) :1488-1494